These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 21542664)

  • 1. Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.
    Robson P
    Expert Opin Drug Saf; 2011 Sep; 10(5):675-85. PubMed ID: 21542664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.
    Schoedel KA; Chen N; Hilliard A; White L; Stott C; Russo E; Wright S; Guy G; Romach MK; Sellers EM
    Hum Psychopharmacol; 2011 Apr; 26(3):224-36. PubMed ID: 21671456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?
    Wade D
    Expert Rev Neurother; 2012 Apr; 12(4 Suppl):9-14. PubMed ID: 22509986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
    Vermersch P
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined cannabinoid therapy via an oromucosal spray.
    Perez J
    Drugs Today (Barc); 2006 Aug; 42(8):495-503. PubMed ID: 16969427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
    Sastre-Garriga J; Vila C; Clissold S; Montalban X
    Expert Rev Neurother; 2011 May; 11(5):627-37. PubMed ID: 21456949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabis; adverse effects from an oromucosal spray.
    Scully C
    Br Dent J; 2007 Sep; 203(6):E12; discussion 336-7. PubMed ID: 17703180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.
    Trigo JM; Lagzdins D; Rehm J; Selby P; Gamaleddin I; Fischer B; Barnes AJ; Huestis MA; Le Foll B
    Drug Alcohol Depend; 2016 Apr; 161():298-306. PubMed ID: 26925704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.
    Aragona M; Onesti E; Tomassini V; Conte A; Gupta S; Gilio F; Pantano P; Pozzilli C; Inghilleri M
    Clin Neuropharmacol; 2009; 32(1):41-7. PubMed ID: 18978501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sativex for the management of multiple sclerosis symptoms.
    Perras C
    Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subjective and physiological effects after controlled Sativex and oral THC administration.
    Karschner EL; Darwin WD; McMahon RP; Liu F; Wright S; Goodwin RS; Huestis MA
    Clin Pharmacol Ther; 2011 Mar; 89(3):400-7. PubMed ID: 21289620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabis derivatives and pain. A small role for delta9-tetrahydrocannabinol (THC) in some forms of multiple sclerosis.
    Prescrire Int; 2009 Oct; 18(103):226. PubMed ID: 19882800
    [No Abstract]   [Full Text] [Related]  

  • 14. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
    Keating GM
    Drugs; 2017 Apr; 77(5):563-574. PubMed ID: 28293911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
    Flachenecker P
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):15-9. PubMed ID: 23369055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
    Oreja-Guevara C
    Expert Rev Neurother; 2012 Apr; 12(4 Suppl):3-8. PubMed ID: 22509985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.
    Russo EB; Guy GW; Robson PJ
    Chem Biodivers; 2007 Aug; 4(8):1729-43. PubMed ID: 17712817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A drug discovery case history of 'delta-9-tetrahydrocannabinol, cannabidiol'.
    Tanasescu R; Rog D; Constantinescu CS
    Expert Opin Drug Discov; 2011 Apr; 6(4):437-52. PubMed ID: 22646020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
    Barnes MP
    Expert Opin Pharmacother; 2006 Apr; 7(5):607-15. PubMed ID: 16553576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.